1365-2710/asset/olbannerleft.jpg?v=1&s=aa84a968ef3e4c88817d0563e21aefa7efa42137)
1365-2710/asset/olbannerright.jpg?v=1&s=a095a2371a8570a4bffe4e80a3cfc0890f8e5615)
Effect of MKC-733, a 5-HT3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study
Article first published online: 30 NOV 2005
DOI: 10.1111/j.1365-2710.2005.00695.x
Additional Information
How to Cite
Fujita, T., Yokota, S., Sawada, M., Majima, M., Ohtani, Y. and Kumagai, Y. (2005), Effect of MKC-733, a 5-HT3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. Journal of Clinical Pharmacy and Therapeutics, 30: 611–622. doi: 10.1111/j.1365-2710.2005.00695.x
Publication History
- Issue published online: 30 NOV 2005
- Article first published online: 30 NOV 2005
- Received 23 September 2004, Accepted 9 February 2005
- Abstract
- Article
- References
- Cited By
Keywords:
- a 5-HT3 receptor agonist;
- bowel motility;
- constipation;
- radio-opaque markers
Summary
Background: MKC-733, a 5-HT3 receptor partial agonist, is a novel enteroprokinetic compound.
Objective: The aim of this study was to explore the effects of MKC-733 on bowel motility and symptoms in a small group of subjects with constipation. Tolerability was also examined.
Methods: The study was conducted in a single-blind and dose-escalation manner on 14 male and female subjects with constipation aged 22–67 years. After a 1 week run-in period, subjects were treated with placebo (b.i.d.) for 1 week, and 0·2 and 0·5 mg of MKC-733 (b.i.d.) for 2 weeks sequentially. Geometric mean and per cent elimination of surrogate markers of bowel motility were measured by a radio-opaque marker technique at the end of each treatment period. They were analysed on the whole group and subgroups with low (n = 6) and high (n = 8) bowel motility based upon the geometric mean value after placebo treatment. Subjects kept diaries of their bowel habits and gastrointestinal symptoms.
Results: Percent elimination increased after treatment with 0·5 mg MKC-733 compared with placebo treatment in the whole group (70·4 ± 33·5% vs. 47·1 ± 36·6%, mean ± SD, P < 0·05). In the low bowel motility group, both geometric mean and percent elimination increased after treatment with 0·5 mg MKC-733 compared with placebo (7·1 ± 0·9 vs. 5·9 ± 0·5, P < 0·05; 60·0 ± 35·8% vs. 13·3 ± 19·4%, P < 0·05). Stool frequency increased after the first-week treatment with MKC-733 compared with placebo (P < 0·05). Numbers of sensation of incomplete evacuation and gastrointestinal symptoms decreased to half and less after the treatment with MKC-733. No serious adverse effect was noted.
Conclusion: Multiple doses of 0·5 mg MKC-733 improve bowel motility, which was clearly demonstrated in the subjects with decreased bowel motility. MKC-733 at the doses studied might be effective in increasing stool frequency and reduce gastrointestinal symptoms related to constipation. MKC-733 was well tolerated. Further studies will be needed to clarify efficacy and safety of MKC-733 on a larger population.